COMMUNIQUÉS West-GlobeNewswire

-
Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
04/06/2018 -
RadNet, Inc. to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018
04/06/2018 -
Ossur Hf : Transactions in relation to share buyback program
04/06/2018 -
Sensorion’s Chair of Scientific Advisory Board, Prof. Christine Petit, Awarded 2018 Kavli Prize in Neuroscience
04/06/2018 -
Veloxis Partners with the American Society of Transplant Surgeons to Award First Annual ASTS-Veloxis Fellowship in Transplantation
04/06/2018 -
Helsinn: Second Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Rajiv Agarwal, MD, Memorial Sloan Kettering Cancer Center
04/06/2018 -
Shire plc : Director/PDMR Shareholding
04/06/2018 -
Ernst & Young LLP (EY) Announces Nelipak CEO Mike Kelly as Entrepreneur of the Year® 2018 Award Finalist for New England Region
04/06/2018 -
VAYA™ Pharma Launches Vayarin® Plus Medical Food for the Management of ADHD in Adults and Adolescents
04/06/2018 -
Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018
04/06/2018 -
TG Therapeutics, Inc. Announces Umbralisib Clinical Data Presentation at the 54th Annual Meeting of the American Society of Clinical Oncology
04/06/2018 -
Stelis Biopharma and Oncobiologics to Unveil Bio2Source CDMO Offering at BIO 2018
04/06/2018 -
CapsoVision Announces U.S. Distribution Partnership With PENTAX Medical
04/06/2018 -
Adverum Biotechnologies to Present at the 2018 Jefferies Global Healthcare Conference
04/06/2018 -
"This is Infertility" Releases New Episodes for Pride Month 2018
04/06/2018 -
Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting
04/06/2018 -
New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
04/06/2018 -
CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody™ Platform and CX-072 at 2018 ASCO Annual Meeting
04/06/2018 -
Analogic Announces Results for the Third Quarter Ended April 30, 2018
04/06/2018
Pages